Innate Pharma S.A. (IPHA)
NASDAQ: IPHA
· Real-Time Price · USD
2.11
-0.07 (-3.21%)
At close: Aug 15, 2025, 3:59 PM
2.12
0.47%
After-hours: Aug 15, 2025, 04:00 PM EDT
Innate Pharma S.A. Balance Sheet Statement
Financials in EUR. Fiscal
year is
January - December.
| Fiscal Year | Q4 2024 | Q2 2024 | Q4 2023 | Q2 2023 | Q4 2022 | Q2 2022 | Q4 2021 | Q2 2021 |
| Period Ending | Dec 31, 2024 | Jun 30, 2024 | Dec 31, 2023 | Jun 30, 2023 | Dec 31, 2022 | Jun 30, 2022 | Dec 31, 2021 | Jun 30, 2021 |
Cash & Equivalents | 66.4M | 69.99M | 70.61M | 71.41M | 84.22M | 102.95M | 103.76M | 103.98M |
Short-Term Investments | 14.37M | 21.81M | 21.85M | 17.48M | 17.26M | 20.4M | 16.08M | 15.34M |
Long-Term Investments | 10.28M | 10.35M | 9.8M | 35.79M | 35.12M | 34.81M | 39.88M | 40.08M |
Other Long-Term Assets | 9.9M | 14.56M | 10.64M | 965K | 14.25M | 13.24M | 29.97M | 34.96M |
Receivables | 1.64M | 393K | 15.23M | 2.93M | 3.08M | 41.83M | 846K | 3.6M |
Inventory | n/a | n/a | n/a | -6.47M | -2K | n/a | -4.95M | n/a |
Other Current Assets | n/a | 16.39M | 1K | 49.3M | 30.59M | n/a | 14.99M | n/a |
Total Current Assets | 85.74M | 111.59M | 148.01M | 144.46M | 139.83M | 171.8M | 138.26M | 129.69M |
Property-Plant & Equipment | 5.13M | 5.75M | 6.32M | 7.26M | 8.54M | 9.56M | 10.17M | 10.89M |
Goodwill & Intangibles | n/a | 119K | 416K | 903K | 1.56M | 43.25M | 44.19M | 45.19M |
Total Long-Term Assets | 25.32M | 39.9M | 27.18M | 54.59M | 68.03M | 108.63M | 129.24M | 136.53M |
Total Assets | 111.06M | 151.5M | 184.19M | 199.05M | 207.86M | 280.43M | 267.5M | 266.22M |
Account Payables | 7.92M | 8.75M | 8.56M | 9.87M | 13.66M | 12.92M | 14.73M | 11.18M |
Deferred Revenue | 616K | n/a | 5.87M | 5.05M | 6.56M | 9.09M | 12.5M | 10.46M |
Short-Term Debt | 8.44M | 8.51M | 8.45M | 5.33M | 1.26M | 30.85M | 29.94M | 2.02M |
Other Current Liabilities | 7.65M | 20.54M | 16.27M | 17.41M | 19.02M | 20.69M | 21.91M | 18.95M |
Total Current Liabilities | 32.98M | 38.22M | 39.64M | 37.67M | 41.34M | 73.56M | 79.89M | 42.62M |
Long-Term Debt | 22.18M | 26.41M | 30.61M | 35.32M | 38.93M | 12.52M | 11.49M | 14.48M |
Other Long-Term Liabilities | 44.13M | 57.9M | 48.07M | 52.55M | 55.74M | 61.9M | 36.23M | 42.55M |
Total Long-Term Liabilities | 69.24M | 84.48M | 83.65M | 103.52M | 112.37M | 90.54M | 80.17M | 90.04M |
Total Liabilities | 102.22M | 122.7M | 132.29M | 141.19M | 153.71M | 164.1M | 160.06M | 132.66M |
Total Debt | 31M | 35.5M | 39.89M | 40.66M | 42.25M | 43.37M | 44.25M | 16.5M |
Common Stock | 4.19M | 4.05M | 4.04M | 4.03M | 4.01M | 3.99M | 3.98M | 3.95M |
Retained Earnings | -386.36M | -361.66M | -336.89M | -328.6M | -330.32M | -265.94M | -272.21M | -244.15M |
Comprehensive Income | 27K | 355K | 495K | 1.06M | 819K | 284K | 456K | 715K |
Shareholders Equity | 8.83M | 28.8M | 51.9M | 57.86M | 54.15M | 116.33M | 107.44M | 133.56M |
Total Investments | 24.66M | 32.16M | 31.65M | 53.27M | 52.38M | 55.21M | 55.96M | 55.42M |